Crinetics Pharmaceuticals, Inc.
CRNX
$84.70
$0.260.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -501.61M | -496.39M | -465.32M | -423.10M | -369.83M |
| Total Depreciation and Amortization | 4.24M | 4.13M | 3.89M | 3.68M | 3.44M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.23M | 89.91M | 78.66M | 74.46M | 69.99M |
| Change in Net Operating Assets | -16.38M | -11.82M | 4.84M | -6.94M | -7.59M |
| Cash from Operations | -422.52M | -414.17M | -377.92M | -351.89M | -304.00M |
| Capital Expenditure | -2.66M | -5.34M | -5.76M | -6.33M | -6.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.49M | 12.85M | 179.67M | -418.95M | -563.50M |
| Cash from Investing | -4.15M | 7.51M | 173.91M | -425.29M | -569.49M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 428.50M | 426.63M | 40.61M | 569.84M | 625.58M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -578.00K | -578.00K | -- | 967.00K | -527.00K |
| Cash from Financing | 427.92M | 426.05M | 40.61M | 570.81M | 625.05M |
| Foreign Exchange rate Adjustments | 18.00K | -114.00K | -106.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.27M | 19.27M | -163.51M | -206.37M | -248.44M |